Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria . The study was conducted in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma whose disease had progressed on or after treatment with brentuximab vedotin.

http://ift.tt/12SK48T